Literature DB >> 25707738

Flow cytometry detection of vitamin D receptor changes during vitamin D treatment in Crohn's disease.

M Bendix1, A Dige1, B Deleuran2, J F Dahlerup1, S P Jørgensen3, L E Bartels4, L B Husted5, T Harsløf5, B Langdahl5, J Agnholt1.   

Abstract

Crohn's disease (CD) is a chronic inflammatory disease associated with a dysregulated T cell response towards intestinal microflora. Vitamin D has immune modulatory effects on T cells through the nuclear vitamin D receptor (VDR) in vitro. It is unclear how oral vitamin D treatment affects VDR expression. The aim of this study was to establish a flow cytometry protocol, including nuclear and cytoplasmic VDR expression, and to investigate the effects of vitamin D treatment on T cell VDR expression in CD patients. The flow cytometry protocol for VDR staining was developed using the human acute monocytic leukaemia cell line (THP-1). The protocol was evaluated in anti-CD3/CD28-stimulated peripheral blood mononuclear cells (PBMCs) from vitamin D3- (n = 9) and placebo-treated (n = 9) CD patients. Anti-VDR-stained PBMCs were examined by flow cytometry, and their cytokine production was determined by cytokine bead array. VDR, CYP27B1 and RXRα mRNA expression levels in CD4(+) T cells were measured by quantitative reverse transcriptase polymerase chain reaction. The flow cytometry protocol enabled detection of cytoplasmic and nuclear VDR expression. The results were confirmed by confocal microscopy and supported by correlation with VDR mRNA expression. VDR expression in CD4(+) T cells increased following stimulation. This VDR up-regulation was inhibited with 30% by vitamin D treatment compared to placebo in CD patients (P = 0027). VDR expression was correlated with in-vitro interferon-γ production in stimulated PBMCs (P = 0.01). Flow cytometry is a useful method with which to measure intracellular VDR expression. Vitamin D treatment in CD patients reduces T cell receptor-mediated VDR up-regulation.
© 2015 British Society for Immunology.

Entities:  

Keywords:  Crohn's disease; T cells; VDR; flow cytometry; vitamin D

Mesh:

Substances:

Year:  2015        PMID: 25707738      PMCID: PMC4469152          DOI: 10.1111/cei.12613

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  38 in total

1.  Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response.

Authors:  Philip T Liu; Steffen Stenger; Huiying Li; Linda Wenzel; Belinda H Tan; Stephan R Krutzik; Maria Teresa Ochoa; Jürgen Schauber; Kent Wu; Christoph Meinken; Diane L Kamen; Manfred Wagner; Robert Bals; Andreas Steinmeyer; Ulrich Zügel; Richard L Gallo; David Eisenberg; Martin Hewison; Bruce W Hollis; John S Adams; Barry R Bloom; Robert L Modlin
Journal:  Science       Date:  2006-02-23       Impact factor: 47.728

2.  Mutations in the AF-2 region abolish ligand-induced intranuclear immobilization of the liver X receptor alpha.

Authors:  Kirsten Prüfer; Christian Hernandez; Matthew Gilbreath
Journal:  Exp Cell Res       Date:  2008-05-27       Impact factor: 3.905

3.  Late Crohn's disease patients present an increase in peripheral Th17 cells and cytokine production compared with early patients.

Authors:  M Veny; M Esteller; E Ricart; J M Piqué; J Panés; A Salas
Journal:  Aliment Pharmacol Ther       Date:  2009-12-03       Impact factor: 8.171

4.  Preparation and properties of clickable amino analogues of the duocarmycins: factors that affect the efficiency of their fluorescent labelling of DNA.

Authors:  Moana Tercel; Sarah P McManaway; H D Sarath Liyanage; Frederik B Pruijn
Journal:  ChemMedChem       Date:  2014-07-17       Impact factor: 3.466

5.  The relation between acute changes in the systemic inflammatory response and plasma 25-hydroxyvitamin D concentrations after elective knee arthroplasty.

Authors:  David Reid; Barry J Toole; Susan Knox; Dinesh Talwar; Johann Harten; Denis St J O'Reilly; Scott Blackwell; John Kinsella; Donald C McMillan; A Michael Wallace
Journal:  Am J Clin Nutr       Date:  2011-03-16       Impact factor: 7.045

6.  Vitamin D: a negative acute phase reactant.

Authors:  Jenna Louise Waldron; Helen L Ashby; Michael P Cornes; Julia Bechervaise; Cyrus Razavi; Osmond L Thomas; Sanjiv Chugh; Shreeram Deshpande; Clare Ford; Rousseau Gama
Journal:  J Clin Pathol       Date:  2013-03-01       Impact factor: 3.411

7.  Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR).

Authors:  M Niessner; B A Volk
Journal:  Clin Exp Immunol       Date:  1995-09       Impact factor: 4.330

8.  Clinical trial: vitamin D3 treatment in Crohn's disease - a randomized double-blind placebo-controlled study.

Authors:  S P Jørgensen; J Agnholt; H Glerup; S Lyhne; G E Villadsen; C L Hvas; L E Bartels; J Kelsen; L A Christensen; J F Dahlerup
Journal:  Aliment Pharmacol Ther       Date:  2010-05-11       Impact factor: 8.171

9.  Oral vitamin D3 supplementation reduces monocyte-derived dendritic cell maturation and cytokine production in Crohn's disease patients.

Authors:  Lars E Bartels; Mia Bendix; Christian L Hvas; Søren P Jørgensen; Jørgen Agnholt; Ralf Agger; Jens F Dahlerup
Journal:  Inflammopharmacology       Date:  2013-12-29       Impact factor: 4.473

10.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.

Authors:  Jo Vandesompele; Katleen De Preter; Filip Pattyn; Bruce Poppe; Nadine Van Roy; Anne De Paepe; Frank Speleman
Journal:  Genome Biol       Date:  2002-06-18       Impact factor: 13.583

View more
  8 in total

1.  Transcriptomic analysis of vitamin D responses in uterine and peripheral NK cells.

Authors:  J A Tamblyn; L E Jeffery; R Susarla; D M Lissauer; S L Coort; A Muñoz Garcia; K Knoblich; A L Fletcher; J N Bulmer; M D Kilby; M Hewison
Journal:  Reproduction       Date:  2019-08       Impact factor: 3.906

2.  Vitamin D increases programmed death receptor-1 expression in Crohn's disease.

Authors:  Mia Bendix; Stinne Greisen; Anders Dige; Christian L Hvas; Nina Bak; Søren P Jørgensen; Jens F Dahlerup; Bent Deleuran; Jørgen Agnholt
Journal:  Oncotarget       Date:  2017-04-11

3.  Impact of vitamin D on the hospitalization rate of Crohn's disease patients seen at a tertiary care center.

Authors:  Krishna V R Venkata; Sumant S Arora; Feng-Long Xie; Talha A Malik
Journal:  World J Gastroenterol       Date:  2017-04-14       Impact factor: 5.742

Review 4.  Efficacy of vitamin D in treatment of inflammatory bowel disease: A meta-analysis.

Authors:  Jinzhong Li; Ning Chen; Dan Wang; Jie Zhang; Xiaobing Gong
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817

5.  Seven Weeks of High-Dose Vitamin D Treatment Reduces the Need for Infliximab Dose-Escalation and Decreases Inflammatory Markers in Crohn's Disease during One-Year Follow-Up.

Authors:  Mia Bendix; Anders Dige; Søren Peter Jørgensen; Jens Frederik Dahlerup; Bo Martin Bibby; Bent Deleuran; Jørgen Agnholt
Journal:  Nutrients       Date:  2021-03-26       Impact factor: 5.717

6.  Vitamin D Effects on Selected Anti-Inflammatory and Pro-Inflammatory Markers of Obesity-Related Chronic Inflammation.

Authors:  Maria Krajewska; Ewelina Witkowska-Sędek; Małgorzata Rumińska; Anna Stelmaszczyk-Emmel; Maria Sobol; Anna Majcher; Beata Pyrżak
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-13       Impact factor: 6.055

Review 7.  Vitamin D in Inflammatory Bowel Diseases. Mechanisms of Action and Therapeutic Implications.

Authors:  Filippo Vernia; Marco Valvano; Salvatore Longo; Nicola Cesaro; Angelo Viscido; Giovanni Latella
Journal:  Nutrients       Date:  2022-01-09       Impact factor: 5.717

Review 8.  Causal Links between Hypovitaminosis D and Dysregulation of the T Cell Connection of Immunity Associated with Obesity and Concomitant Pathologies.

Authors:  Natalia Todosenko; Maria Vulf; Kristina Yurova; Olga Khaziakhmatova; Larisa Mikhailova; Larisa Litvinova
Journal:  Biomedicines       Date:  2021-11-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.